Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethinylestradiol + chlormadinone acetate + metformin
- Development stage
- Unknown
- Lead developer
- Universidade de São Paulo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of the biguanide insulin sensitizer metformin and a combined oral contraceptive containing ethinylestradiol and chlormadinone acetate. It is being investigated by the University of Sao Paulo for the management of polycystic ovary syndrome (PCOS). Metformin works by activating AMP-activated protein kinase (AMPK), which improves insulin sensitivity and reduces hyperinsulinemia-driven androgen production. Ethinylestradiol, a synthetic estrogen, increases sex hormone-binding globulin (SHBG) levels to lower free testosterone, while chlormadinone acetate, a progestin with anti-androgenic properties, acts as an antagonist at the androgen receptor. Together, these agents aim to regulate the menstrual cycle, treat clinical symptoms of hyperandrogenism such as hirsutism and acne, and improve metabolic and cardiovascular risk markers in women with PCOS.
- Other names
- metformin + ethinylestradiol + chlormadinone acetatemetformin + EE/CMA
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PR (Progesterone receptor)ER (Estrogen receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on ethinylestradiol + chlormadinone acetate + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethinylestradiol + chlormadinone acetate + metformin.